Navigation Links
Isolagen Modifies Ongoing Clinical Program for Acne Scars
Date:11/27/2007

- FDA Recommends Further Analysis of Evaluator Assessment Scale and Photo Guide; Company Proposes Amending Previously Announced Phase III Study as a

Phase II/III Study - - No Impact on Ongoing Pivotal Phase III Clinical Program in Wrinkles -

EXTON, Pa., Nov. 27 /PRNewswire-FirstCall/ -- Isolagen(TM), Inc. (Amex: ILE) announced today that the Food and Drug Administration (FDA) has provided follow-up on the Phase III program investigating the Isolagen Therapy(TM) for the treatment of moderate to severe acne scars. The FDA reiterated that there are no safety issues that would prevent the initiation of the proposed studies. However, the FDA asked the Company to further clarify certain protocol issues and raised questions related to the acne scar Evaluator Assessment Scale and Photo Guide. The FDA recommended that in order to address these issues, the Company should conduct a Phase II study; therefore, the Company will propose modifying the ongoing Phase III Study IT- A-008 as a Phase II/III study (as discussed further below). The FDA requests are specific to the acne scar clinical program and do not impact the Company's ongoing, pivotal Phase III clinical program evaluating the Isolagen Therapy for the treatment of nasolabial folds, or wrinkles.

Isolagen's two randomized, double-blind, placebo-controlled acne scar clinical trials (IT-A-008 and IT-A-009) of approximately 120 patients each were designed and powered as Phase III studies. Based on this additional information from the FDA, Isolagen will propose to modify the initiated study IT-A-008 to be a Phase II/III study. This study, which is designed to demonstrate efficacy, will be amended to allow for a closer assessment of the Evaluator Assessment Scale and Photo Guide. Based on the study's findings, the Company will propose to continue with the acne scar pivotal clinical program during 2008. Isolagen believes that the two trials may have the potential to form the b
'/>"/>

SOURCE Isolagen, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Isolagen, Inc. Postpones Annual Meeting
2. Isolagen Initiates Phase III Clinical Program to Investigate Isolagen Therapy(TM) for the Treatment of Acne Scars
3. CNS Response, Inc. Modifies rEEG(SM) Trial Protocol for Treatment-Resistant Depression Study
4. Middle School Marks Most Critical Time to Start Ongoing Conversations About Drug and Alcohol Use With Kids
5. Dr. Dan L. Fortenbacher, O.D., FCOVD, Becomes 29th President of College of Optometrists in Vision Development (COVD); Unveils 7-Part Development Plan for Ongoing Growth
6. Radiologists encouraged to look beyond cancer for clinically unseen diseases
7. Clinical depression linked to abnormal emotional brain circuits
8. Preclinical study suggests organ-transplant drug may aid in lupus fight
9. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
10. Good Clinical Practice Journal Awards: Winners Announced
11. Microsoft Helps Developers of Clinical User Interfaces Improve Efficiency, Patient Safety With Free Toolkit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2013)... a few extra cups of coffee each month might ... known as primary sclerosing cholangitis (PSC), a new study ... Minn., found that drinking coffee was associated with a ... to cirrhosis of the liver, liver failure and biliary ... relationship. "While rare, PSC has extremely detrimental ...
(Date:5/18/2013)... a May 14, 2013 article entitled “Angelina Jolie Reveals ... Fox News reported the movie star had opted to ... gene that doctors estimated gave her an 87 percent ... of ovarian cancer (go to: goo.gl/5JHBP). Ms. Jolie’s personal ... blog post entitled “A Patient’s Journey: Angelina Jolie” that ...
(Date:5/18/2013)... May 18, 2013 The Communities of ... special places we call home. These are the townships, villages ... are the locations where the people are friendly and neighbors ... viewers off the highways and shares the best in both ... nations with an American sports and film celebrity. It airs ...
(Date:5/18/2013)... Washington DC (PRWEB) May 18, 2013 Family ... Best" designation for excellence by Follow Media Consulting, Inc. in ... award signifies the continued commitment and dedication of the areas ... lifestyle. , No one knows parenting better than Brenda Hyde, ... goal is to help parents know about the vast resources ...
(Date:5/18/2013)... (PRWEB) May 18, 2013 The “Sleep ... Pulse Oximeters, CPAP, Masks, Adaptive Servo-Ventilation (ASV), Oral Appliances, ... Forecast to 2017” analyzes and studies the major market ... and Rest of the World. , Browse , ... 16 Figures , 318 ...
Breaking Medicine News(10 mins):Health News:Study Links Coffee to Lower Risk for Rare Liver Disease 2Health News:Angelina Jolie – Scarless Breast Augmentation Surgery 2Health News:Communities of Distinction TV Presents "A Place to Call Home" Segment 2Health News:Summer Camps in DC "Best of the Best" Awarded to Family Magazine of Washington DC for Excellence by Follow Media Consulting, Inc. 2Health News:Sleep Apnea Devices Market to reach $19.72 Billion by 2017 - New Report by MarketandMarkets 2Health News:Sleep Apnea Devices Market to reach $19.72 Billion by 2017 - New Report by MarketandMarkets 3
... by aiding in senior health and ... ... in market research for the health insurance industry, today,announced the release of ... and over population. SrHRA provides,proven health risk stratification measures based on self-reported,information ...
... ... benefits plans, COLUMBIA, S.C., Jan. 9 One of ... and a clearer message.,Colonial Life & Accident Insurance Company today ... who the company is and what it,does., (Logo: ...
... Expected results include higher quality care, increased ... Group Health Incorporated (GHI) and,Health Plan of New York ... first of its kind in New York, that will provide ... to become Medical,Home Practices. GHI and HIP see this as ...
... Diego, January 8, 2008 ?Eating out instead of cooking ... the American diet. Americans face a large variety of ... out. Do the choices of available restaurants matter ... the February 2008 issue of the American Journal of ...
... could improve understanding of irritable bowel syndrome and lead ... News) -- Women with irritable bowel syndrome anticipate and ... new study suggests. , The University of California, ... effectively switch off a pain modulation mechanism in the ...
... Reduce Stiffness for Better Health with,Innovative ,Sleep and ... FORT LAUDERDALE, Fla., Jan. 9 Contour ... people implement an,ergonomic makeover into their life for ... well being. By aligning the body, relieving,pressure points ...
Cached Medicine News:Health News:DSS Research Announces Senior Health Risk Assessment Tool 2Health News:New Colonial Life Brand Clarifies Company's Strengths 2Health News:New Colonial Life Brand Clarifies Company's Strengths 3Health News:GHI and HIP Launch Pilot Medical Home Network Project with Support from Commonwealth Fund 2Health News:GHI and HIP Launch Pilot Medical Home Network Project with Support from Commonwealth Fund 3Health News:Eating out can have both positive and negative impact on obesity 2Health News:Women With IBS Unable to Switch Off Pain Response 2Health News:Renew, Relax & Align the Body with an Ergonomic Makeover 2Health News:Renew, Relax & Align the Body with an Ergonomic Makeover 3
(Date:5/16/2013)... NORTH CHICAGO, Ill. and MECHELEN, ... NV (Euronext: GLPG) and AbbVie (NYSE: ABBV ... development collaboration to include Crohn,s disease.  Galapagos will fund ... which is designed to facilitate rapid progression into Phase ... Q2 2015, AbbVie will pay Galapagos $50 million.  The ...
(Date:5/16/2013)... and SYDNEY , May 16, ... - ASX: HIN), a leading innovator of less invasive, miniaturized ... heart failure, today announced that CEO Doug Godshall ... Global Healthcare Conference at 11:00 a.m. EDT on Monday, May ... at the Sheraton New York Hotel. A live ...
(Date:5/16/2013)... JACKSONVILLE, Florida , May 16, 2013 ... private practice in the U.S. to access the widely-used ... just a PC and Internet connection to get started. ... pre-operative planning software for over 10 years, is dedicated ... to template with digital x-ray images, when printed film ...
Breaking Medicine Technology:AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 2AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 3AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 4AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 5AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 6HeartWare Presentation At The 2013 UBS Global Healthcare Conference To Be Webcast 2OrthoView Announces the U.S. Launch of a New, Subscription-based, Digital Planning and Templating Solution for Individual Orthopaedic Surgeons 2
... The ERATO study,published today in the ... in patients with permanent atrial fibrillation, that ... rate, on top of,other rate control agents. ... beats per,minute (p< 0, 0001) with dronedarone ...
... Landmark ARB trial investigated Micardis(R) (telmisartan) against ... endpoint of cardiovascular death, myocardial, infarction, stroke ... ACE, inhibitor intolerant high-risk patients receiving current ... 31 The primary results of the,TRANSCEND(TM)* ...
Cached Medicine Technology:American Heart Journals Publishes Results From ERATO Trial Showing Dronedarone (Multaq(R)) Improves Ventricular Rate Control in Patients With Permanent Atrial Fibrillation 2American Heart Journals Publishes Results From ERATO Trial Showing Dronedarone (Multaq(R)) Improves Ventricular Rate Control in Patients With Permanent Atrial Fibrillation 3TRANSCEND(TM) Trial Results Presented at European Society of Cardiology Congress and Published in The Lancet 2TRANSCEND(TM) Trial Results Presented at European Society of Cardiology Congress and Published in The Lancet 3TRANSCEND(TM) Trial Results Presented at European Society of Cardiology Congress and Published in The Lancet 4TRANSCEND(TM) Trial Results Presented at European Society of Cardiology Congress and Published in The Lancet 5TRANSCEND(TM) Trial Results Presented at European Society of Cardiology Congress and Published in The Lancet 6TRANSCEND(TM) Trial Results Presented at European Society of Cardiology Congress and Published in The Lancet 7
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: